EDAP TMS S.A. (EDAP)
EDAP Reports Third Quarter 2025 Financial Results
Cybin Inc (CYBN)
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
Catalyst Biosciences Inc. (CBIO)
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Collegium Pharmaceutical Inc (COLL)
Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance
Lexicon Pharmaceuticals Inc. (LXRX)
Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
Organon & Co. (OGN)
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Johnson & Johnson (JNJ)
FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
Silence Therapeutics Plc (SLN)
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
uniQure NV (QURE)
uniQure to Announce Third Quarter 2025 Financial Results